Innovating Works
PB_LC: Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC) PULMOBIOTICS tramitó un HORIZON EUROPE: HORIZON-EIC-2022-TRANSITION-01 Non-small-cNon-small-cell carcinomas (NSCLC) represent 80-85% of the worldwide lung cancer cases, which are the leading cause of cancer-rela...
2022-10-26 - 2025-06-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.